Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C.
Sammy SaabDarshan A MehtaStacie HudgensNathan GrunowYanjun BaoBrett PinskyPublished in: Liver international : official journal of the International Association for the Study of the Liver (2018)
During the active treatment period, small but statistically significant decrements in health-related quality of life outcomes were observed potentially driven by ribavirin, which were not sustained during the post-treatment follow-up period. Differences were observed by patient subgenotype, where health-related quality of life improvements were consistently higher for genotype 1b patients as compared to genotype 1a patients.